IGHE and asthma: The INNOVATE study (INvestigation of Omalizumab in seVere Asthma TrEatment) revealed that omalizumab withdrawal after 28 weeks of therapy led to the re-emergence of asthma symptoms, which correlated well with increasing free IgE and decreasing concentrations of the drug in serum.